NCT06832982 2026-04-09
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
Phase 1 Recruiting
Clinical Trials
44 trialsNCT06657144 2026-04-06
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05635643 2026-03-19
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT06283134 2026-01-07
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Not yet recruiting
NCT05427396 2025-12-03
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT06882876 2025-09-19
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
Xiangya Hospital of Central South University
Phase 1 Enrolling by invitation
NCT07004244 2025-06-24
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Sichuan University
Phase 1 Recruiting
NCT04991506 2025-06-23
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Completed
NCT05657418 2025-06-06
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT05757492 2025-05-01
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Terminated
NCT05167071 2025-04-27
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1 Active not recruiting
NCT05021328 2025-02-07
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Hubei Cancer Hospital
Phase 1 Completed
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT06389526 2024-09-19
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Coherus Oncology, Inc.
Phase 1 Not yet recruiting
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT06283303 2024-02-29
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Unknown
NCT04137900 2024-02-05
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Unknown
NCT04473716 2023-11-22
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT06078982 2023-10-12
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Shanghai East Hospital
Phase 1 Unknown
NCT04737122 2023-10-10
Study of LM-061 in Subjects in Advanced Tumors
LaNova Medicines Limited
Phase 1 Terminated
NCT04357756 2023-09-13
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05451407 2023-07-07
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05650203 2023-04-05
A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Withdrawn
NCT03732664 2023-03-24
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Completed
NCT05502393 2022-08-16
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT05253105 2022-05-31
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Withdrawn
NCT05369286 2022-05-11
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Maxinovel Pty., Ltd.
Phase 1 Unknown
NCT04073784 2022-04-26
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1 Unknown
NCT05061628 2021-09-29
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT04731038 2021-09-17
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
Phase 1 Unknown
NCT04773951 2021-08-24
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT04947241 2021-07-01
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 1 Unknown
NCT04926753 2021-06-16
Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
Ruijin Hospital
Phase 1 Unknown
NCT04819516 2021-03-29
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT04197882 2021-02-10
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT03316144 2020-09-30
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed
NCT04193098 2020-07-07
Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT04072900 2020-04-28
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Phase 1 Unknown
NCT02836834 2019-10-22
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown